Literature DB >> 153156

Precocious aging and dementia in patients with Down's syndrome.

K Wisniewski, J Howe, D G Williams, H M Wisniewski.   

Abstract

Fifty unselected institutionalized patients with Down's syndrome were studied to determine the clinical course of precocious aging and mental and neurological deterioration. In our studies we establish statistically significant differences in neurological and psychiatric abnormalities and mental deterioration in patients below and above age 35, indicating progressive changes in the central nervous system. We demonstrate higher incidence of recent memory loss, impairment of short-term visual retention, frontal release signs, hypertonia, hyperreflexia, long-tract signs, and psychiatric problems. We also note the presence of external features of precocious aging. Down's syndrome appears to be a human chromosomal abnormality in which genetically determined biochemical defects leading to precocious aging and dementia can be studied.

Entities:  

Mesh:

Year:  1978        PMID: 153156

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  20 in total

Review 1.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

2.  An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

Authors:  Giovanna Cenini; Ada Fiorini; Rukhsana Sultana; Marzia Perluigi; Jian Cai; Jon B Klein; Elizabeth Head; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-08-20       Impact factor: 7.376

Review 3.  Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis.

Authors:  Scott A Small; Sam Gandy
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

Review 4.  Rab GTPases, membrane trafficking and diseases.

Authors:  Guangpu Li
Journal:  Curr Drug Targets       Date:  2011-07-01       Impact factor: 3.465

5.  Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Authors:  Sarah B Martin; Amy L S Dowling; Joann Lianekhammy; Ira T Lott; Eric Doran; M Paul Murphy; Tina L Beckett; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome.

Authors:  M B Schapiro; J V Haxby; C L Grady; R Duara; N L Schlageter; B White; A Moore; M Sundaram; S M Larson; S I Rapoport
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

7.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

8.  Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

Authors:  M Nistor; M Don; M Parekh; F Sarsoza; M Goodus; G E Lopez; C Kawas; J Leverenz; E Doran; I T Lott; M Hill; E Head
Journal:  Neurobiol Aging       Date:  2006-08-09       Impact factor: 4.673

9.  Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway.

Authors:  Carolyn L Fisher; Ross J Resnick; Soumya De; Lucila A Acevedo; Kun Ping Lu; Frank C Schroeder; Linda K Nicholson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 10.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.